Cagrilinitide without a GLP-1: the evidence

Cagrilinitide is an investigational long-acting amylin analogue developed by Novo Nordisk. It is most often discussed as the amylin half of CagriSema, the fixed-ratio combination with semaglutide. But cagrilinitide has also been tested as a standalone injection, and the Phase 2 and Phase 3 data give a reasonably clear picture of what it does on its own^[1].

This article answers the question directly: can cagrilinitide be used without a GLP-1 agonist, what weight loss does the evidence suggest, and does stepping away from GLP-1s resolve the nausea and vomiting that drives people to look for alternatives?

What cagrilinitide is and how it works

Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta-cells. It slows gastric emptying, suppresses post-meal glucagon secretion, and signals satiety through receptors in the area postrema of the brainstem, a region distinct from the GLP-1 receptor pathways that tirzepatide and semaglutide target^[2]. Cagrilinitide is a fatty-acid-acylated amylin analogue engineered for once-weekly subcutaneous dosing, as native amylin has a half-life of minutes.

The different receptor target is the reason people with GLP-1 intolerance ask about it. In principle, an amylin-only approach sidesteps the GLP-1 pathway entirely.

What the monotherapy data shows

The most detailed cagrilinitide monotherapy data comes from a 32-week Phase 2 randomised controlled trial in adults with type 2 diabetes published in the Lancet in August 2023^[1]. The trial included three active arms: once-weekly CagriSema 2.4 mg, once-weekly semaglutide 2.4 mg alone, and once-weekly cagrilinitide 2.4 mg alone.

At 32 weeks the cagrilinitide-alone arm produced a mean weight reduction of 8.1%, compared with 5.1% on semaglutide alone and 15.6% on the combination. The monotherapy figure is clinically meaningful but considerably smaller than CagriSema, which is consistent with the two drugs working through complementary pathways.

The larger REDEFINE 1 Phase 3a trial, published in the New England Journal of Medicine in August 2025, tested CagriSema in 3,417 adults without diabetes^[3]. It also included a cagrilinitide-alone arm (2.4 mg, n=302) and a semaglutide-alone arm (2.4 mg, n=302). The topline result for CagriSema was a 20.4% mean body-weight reduction versus 3.0% on placebo. The trial's pre-specified primary endpoint was for the combination; per-arm monotherapy data from REDEFINE 1 are reported in the supplementary tables but have not been the focus of Novo Nordisk's public readouts.

The GI side-effect question

This is the critical point for anyone considering cagrilinitide as a GLP-1 escape route. The Phase 2 trial reported that gastrointestinal adverse events were the dominant safety signal across all three arms, with 80% of cagrilinitide monotherapy participants reporting at least one GI event, compared with 71% in the semaglutide arm and 68% in the CagriSema arm. Most events were mild or moderate in severity.

A 2026 review of long-acting amylin analogues in the journal Peptides reached a similar conclusion: "gastrointestinal side effects, especially nausea, similar to those reported for GLP-1R agonists are commonplace during initiation and up-titration of amylin analogues but mostly resolve during continued use"^[2]. A 2026 narrative review in Diabetes, Obesity and Metabolism also described cagrilinitide as having a GI profile comparable to GLP-1 agonists^[4].

The mechanism explains why. Amylin acts partly via the area postrema, a circumventricular organ without a blood-brain barrier. GLP-1 agonists activate receptors in the same region. Both pathways converge on nausea and slowed gastric emptying. Switching receptor class does not eliminate the overlap.

Regulatory status as of July 2026

Cagrilinitide is not approved anywhere as a standalone medicine. The FDA has not granted marketing authorisation. The EMA has not issued a central authorisation. There is no MHRA licence. Cagrilinitide circulates in research settings and through grey-market suppliers, but there is no approved product, no approved labelling, and no regulated supply chain for individual use.

CagriSema as a combination product is further along: the REDEFINE programme has completed Phase 3a trials^[3], and Novo Nordisk has stated its intention to file for regulatory approval, but no approval decision had been issued by any major regulator as of the time this article was written.

What we do not yet know

There is no published head-to-head trial of cagrilinitide monotherapy against a GLP-1 agonist at matched weight-loss targets with direct GI tolerability comparisons. The Phase 2 data suggest GI rates may run somewhat higher with cagrilinitide alone than with semaglutide alone (80% vs 71% in that trial), but the population was type 2 diabetes patients, the doses were matched at 2.4 mg, and the study was not designed to answer the tolerability question for people who have already failed GLP-1 therapy.

The community discussion that prompted this article (a Reddit thread asking whether cagrilinitide can substitute for GLP-1s in people who cannot tolerate them) represents a real clinical question that the current trial literature does not directly answer. Anyone considering the switch should discuss their specific GI history with a prescriber before drawing conclusions from the aggregate trial data. Relevant background on the GLP-1 class is on the semaglutide page.